Ruffer LLP Supernus Pharmaceuticals, Inc. Transaction History
Ruffer LLP
- $1.48 Billion
- Q3 2025
A detailed history of Ruffer LLP transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ruffer LLP holds 55,385 shares of SUPN stock, worth $3.16 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
55,385Holding current value
$3.16 Million% of portfolio
0.18%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
324Shares Held
61MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$592 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$354 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$274 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$172 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$157 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $3.05B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...